[zurfer]

It's an interesting industry that needs billions to bring a new drug to market. At the same time it creates a lot of value to a patient. But the manufacturing of a single dose is usually tiny.

Now how do you price that? The profits here will reward pharma investors and enable more investments in RnD of new medicines. I feel that's mostly fair.

[Scene_Cast2]

Some types of software aren't too far from that paradigm.

[AvocadoPanic]

The 'risk' here is often carried by publicly funded research. ~6.2 billion for glp

The private 'investment' comes in manufacturing, scale and marketing.

Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.

[15155]

> Novo Nordisk has spent 41% more on shareholder enrichment (buybacks and dividends) than on R&D over the past five years.

So they are good stewards of their funds and know they can't deploy as much as they have? Berkshire Hathaway does the same thing.

[kingstnap]

The typical other solution for this is government grants for research.

It could work but there are problems in (1) the amount of money required and (2) the funding research -> getting votes pipeline is borked (credit assignment in general is borked).

[dzhiurgis]

Incentive is would be research forever without any results. See how expensive NASA programs were.